IDEAYA Biosciences has partnered with Genentech to test the combination of IDE892, a potential best-in-class PRMT5 inhibitor, with Genentech's KRAS G12D inhibitor RG6620 in patients with pancreatic ductal adenocarcinoma (PDAC) who have MTAP deletions and KRAS G12D mutations. Genentech will sponsor the clinical trial, while IDEAYA will supply IDE892. This collaboration aims to address the high unmet need in PDAC by potentially improving treatment efficacy through targeted combination therapy. The trial represents a strategic step in developing precision oncology treatments for a subset of pancreatic cancer patients lacking approved targeted options.
Bitcoin is currently trading in a narrow range around $64,000 with reduced volatility, as indicated by tightening Bollinger Bands. Traders are watching closely for a breakout, which could push prices toward the $70,000-$72,000 resistance zone, signal...
Globus Medical is rated a buy with a target return of 17.5% over the next year, supported by a stable EV/EBITDA multiple of 10.56x. The company's core business is growing faster than headline figures suggest, with international sales up 18% and gross...
Bitcoin recently climbed back above $64,000, showing resilience despite a weak US equity market and rising long-term Treasury yields. Analysts suggest this marks an accumulation phase, with large holders buying after months of selling and regulatory ...
At the 2026 Jackson Hole Symposium, Kevin Warsh is expected to maintain a dovish outlook, attributing rising nominal rates to increases in real rates rather than inflation concerns. He is unlikely to offer explicit guidance but appears focused on inf...
Hyperliquid is broadening its derivative offerings to include pre-IPO perpetual contracts, allowing traders to speculate on equity valuations before public listings. Early markets reveal significant price gaps at IPOs, highlighting potential demand v...
